



## Summary of Studies Supporting USDA Product Licensure

Establishment Name	Zoetis Inc.
USDA Vet Biologics Establishment Number	190
Product Code	1081.02
True Name	Bordetella Bronchiseptica Vaccine, Avirulent Live Culture
Tradenname(s) / Distributor or Subsidiary (if different from manufacturer)	Vanguard Intranasal Rapid RESP B - No distributor specified Vanguard Intranasal Rapid RESP B SF - No distributor specified
Date of Compilation Summary	December 07, 2017

**Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.**

<b>Study Type</b>	Efficacy																							
<b>Pertaining to</b>	Bordetella bronchiseptica ( <i>B. bronchiseptica</i> )																							
<b>Study Purpose</b>	To demonstrate effectiveness against <i>B. bronchiseptica</i> infection one year after vaccination																							
<b>Product Administration</b>	One dose, administered intranasally																							
<b>Study Animals</b>	Study involved 16 vaccinated and 16 control puppies, 8 weeks of age																							
<b>Challenge Description</b>	Challenged with <i>B. bronchiseptica</i> , one year after vaccination																							
<b>Interval observed after challenge</b>	After challenge, dogs were observed daily 28 days post-challenge.																							
<b>Results</b>	<p>Number of days of coughing Five number summary (<i>Q</i>=quartile)</p> <table border="1"> <thead> <tr> <th rowspan="2">Treatment</th> <th colspan="5">Number of Days Animal Coughed</th> </tr> <tr> <th>Min</th> <th>Q1</th> <th>Median</th> <th>Q3</th> <th>Max</th> </tr> </thead> <tbody> <tr> <td>Control</td> <td>4.0</td> <td>10.0</td> <td>18.0</td> <td>25.5</td> <td>28.0</td> </tr> <tr> <td>Vaccine</td> <td>0.0</td> <td>1.5</td> <td>4.0</td> <td>9.5</td> <td>20.0</td> </tr> </tbody> </table> <p>If coughing was observed at either of the two daily observation periods on a day, that day was positive for coughing.</p> <p>The raw data is shown on the attached page</p>	Treatment	Number of Days Animal Coughed					Min	Q1	Median	Q3	Max	Control	4.0	10.0	18.0	25.5	28.0	Vaccine	0.0	1.5	4.0	9.5	20.0
Treatment	Number of Days Animal Coughed																							
	Min	Q1	Median	Q3	Max																			
Control	4.0	10.0	18.0	25.5	28.0																			
Vaccine	0.0	1.5	4.0	9.5	20.0																			
<b>USDA Approval Date</b>	June 20, 2014																							



<b>Study Type</b>	Efficacy																																		
<b>Pertaining to</b>	Bordetella bronchiseptica ( <i>B. bronchiseptica</i> )																																		
<b>Study Purpose</b>	To demonstrate efficacy against <i>B. bronchiseptica</i> infection																																		
<b>Product Administration</b>	One dose, administered intranasally																																		
<b>Study Animals</b>	Study involved 16 vaccinated and 16 control puppies, 8 weeks of age																																		
<b>Challenge Description</b>	Challenged with <i>B. bronchiseptica</i> , 42 days after vaccination																																		
<b>Interval observed after challenge</b>	After challenge, dogs were observed daily for coughing for 28 days																																		
<b>Results</b>	<p>A dog was considered affected if coughing was observed at least once on 2 or more consecutive days.</p> <p><u>Table 1: Clinical Respiratory Sign (Coughing)</u></p> <table border="1"> <thead> <tr> <th rowspan="2">Treatment</th> <th rowspan="2">Total</th> <th colspan="2">At least 1 day</th> <th colspan="2">At least one occurrence of 2 consecutive days</th> <th colspan="3">Duration</th> </tr> <tr> <th>Positive</th> <th>Negative</th> <th>Positive</th> <th>Negative</th> <th>Q1</th> <th>Median</th> <th>Q3</th> </tr> </thead> <tbody> <tr> <td>Control</td> <td>16</td> <td>16/16 (100%)</td> <td>0/16 (0%)</td> <td>15/16 (94%)</td> <td>1/16 (6%)</td> <td>18.5</td> <td>22.0</td> <td>23.5</td> </tr> <tr> <td>Vaccinated</td> <td>16</td> <td>7/16 (44%)</td> <td>9/16 (56%)</td> <td>0/16 (0%)</td> <td>16/16 (100%)</td> <td>0</td> <td>0</td> <td>9.5</td> </tr> </tbody> </table> <p>Please see attached page for individual raw data.</p>	Treatment	Total	At least 1 day		At least one occurrence of 2 consecutive days		Duration			Positive	Negative	Positive	Negative	Q1	Median	Q3	Control	16	16/16 (100%)	0/16 (0%)	15/16 (94%)	1/16 (6%)	18.5	22.0	23.5	Vaccinated	16	7/16 (44%)	9/16 (56%)	0/16 (0%)	16/16 (100%)	0	0	9.5
Treatment	Total			At least 1 day		At least one occurrence of 2 consecutive days		Duration																											
		Positive	Negative	Positive	Negative	Q1	Median	Q3																											
Control	16	16/16 (100%)	0/16 (0%)	15/16 (94%)	1/16 (6%)	18.5	22.0	23.5																											
Vaccinated	16	7/16 (44%)	9/16 (56%)	0/16 (0%)	16/16 (100%)	0	0	9.5																											
<b>USDA Approval Date</b>	April 18, 2013																																		



<b>Study Type</b>	Safety																																				
<b>Pertaining to</b>	ALL																																				
<b>Study Purpose</b>	To demonstrate safety under conditions of normal use																																				
<b>Product Administration</b>	One dose, administered intranasally																																				
<b>Study Animals</b>	Study involved 674 dogs total, with 239 dogs approximately 7-9 weeks of age and 435 dogs 10 weeks of age or older. Dogs were assigned to one of two lots of vaccine (T01- 309 animals; T02- 305 animals) or to a non-treated control group (T03- 60 animals).																																				
<b>Challenge Description</b>	N/A																																				
<b>Interval observed after challenge</b>	Immediate abnormal health events were assessed for approximately 10-15 minutes post-vaccination and late abnormal health events were assessed for 14 days post-vaccination.																																				
<b>Results</b>	<p>There were no immediate post-vaccination reactions observed in any of the vaccinated groups (T01, T02). There were no abnormal health events associated with the control group (T03).</p> <p><u>Frequency Distribution of Late Abnormal Health Events with dogs administered the product (T01 and T02)</u></p> <table border="1"> <thead> <tr> <th>Clinical Signs Associated with Abnormal Health Event †</th> <th>Number/Total Number of Animals (%)</th> </tr> </thead> <tbody> <tr> <td>Anorexia</td> <td>3/614 (0.49%)</td> </tr> <tr> <td>Ataxia</td> <td>1/614 (0.16%)</td> </tr> <tr> <td>Cough*</td> <td>7/614 (1.14%)</td> </tr> <tr> <td>Cystitis</td> <td>2/614 (0.33%)</td> </tr> <tr> <td>Dermatitis</td> <td>1/614 (0.16%)</td> </tr> <tr> <td>Diarrhea</td> <td>4/614 (0.65%)</td> </tr> <tr> <td>Emesis*</td> <td>3/614 (0.49%)</td> </tr> <tr> <td>Emesis</td> <td>5/614 (0.80%)</td> </tr> <tr> <td>Internal ear disorder (head tilt)</td> <td>1/614 (0.16%)</td> </tr> <tr> <td>Lethargy</td> <td>5/614 (0.81%)</td> </tr> <tr> <td>Nystagmus</td> <td>1/614 (0.16%)</td> </tr> <tr> <td>Otitis externa</td> <td>2/614 (0.33%)</td> </tr> <tr> <td>Pruritis</td> <td>1/614 (0.16%)</td> </tr> <tr> <td>Pyrexia</td> <td>2/614 (0.33%)</td> </tr> <tr> <td>Rhinitis</td> <td>2/614 (0.33%)</td> </tr> <tr> <td>Sneezing*</td> <td>8/614 (1.30%)</td> </tr> <tr> <td>Urticaria**</td> <td>1/614 (0.16%)</td> </tr> </tbody> </table> <p>†One dog accounted for the abnormal health events of anorexia, ataxia, head tilt, nystagmus, lethargy, and otitis externa which was affirmed by licensee to not be related to vaccination.</p> <p>*Mild, transient, and associated with the normal response to vaccination by licensee.</p>	Clinical Signs Associated with Abnormal Health Event †	Number/Total Number of Animals (%)	Anorexia	3/614 (0.49%)	Ataxia	1/614 (0.16%)	Cough*	7/614 (1.14%)	Cystitis	2/614 (0.33%)	Dermatitis	1/614 (0.16%)	Diarrhea	4/614 (0.65%)	Emesis*	3/614 (0.49%)	Emesis	5/614 (0.80%)	Internal ear disorder (head tilt)	1/614 (0.16%)	Lethargy	5/614 (0.81%)	Nystagmus	1/614 (0.16%)	Otitis externa	2/614 (0.33%)	Pruritis	1/614 (0.16%)	Pyrexia	2/614 (0.33%)	Rhinitis	2/614 (0.33%)	Sneezing*	8/614 (1.30%)	Urticaria**	1/614 (0.16%)
Clinical Signs Associated with Abnormal Health Event †	Number/Total Number of Animals (%)																																				
Anorexia	3/614 (0.49%)																																				
Ataxia	1/614 (0.16%)																																				
Cough*	7/614 (1.14%)																																				
Cystitis	2/614 (0.33%)																																				
Dermatitis	1/614 (0.16%)																																				
Diarrhea	4/614 (0.65%)																																				
Emesis*	3/614 (0.49%)																																				
Emesis	5/614 (0.80%)																																				
Internal ear disorder (head tilt)	1/614 (0.16%)																																				
Lethargy	5/614 (0.81%)																																				
Nystagmus	1/614 (0.16%)																																				
Otitis externa	2/614 (0.33%)																																				
Pruritis	1/614 (0.16%)																																				
Pyrexia	2/614 (0.33%)																																				
Rhinitis	2/614 (0.33%)																																				
Sneezing*	8/614 (1.30%)																																				
Urticaria**	1/614 (0.16%)																																				

	**Urticaria occurred six days after administration of the vaccination.
<b>USDA Approval Date</b>	July 09, 2015